Microtubules (MTs) are a highly successful target for anticancer therapy. MT-stabilizing
agents (MSAs) bind to MTs, promoting their polymerization, blocking mitosis, and causing …

Drugs that target microtubules are a successful class of anti-cancer agents that have been in
clinical use for over two decades. Acquired resistance to these drugs, however, remains a …

Abstract Development of antimitotic binding to the colchicine-binding site for the treatment of
cancer is rapidly expanding. Numerous antimicrotubule agents are prepared every year …

The so-called receiver operating characteristic technique is used as a tool in an optimization
procedure for the improvement and assessment of a filter-based methodology for the …

Increased abundance of βII-and βIII-tubulin isotypes in cancer cells confers resistance to
vinca and taxoid site drugs; however, the role of these isotypes in the acquired resistance of …

Differential susceptibility to microtubule agents has been demonstrated between
mammalian cells and kinetoplastid organisms such as Leishmania spp. and Trypanosoma …

Although they play a significant part in the regulation of microtubule structure, dynamics, and
function, the disordered C-terminal tails of tubulin remain invisible to experimental structural …

A crystal structure of the integrase binding domain (IBD) of the lens epithelium‐derived
growth factor (LEDGF/p75) in complex with the dimer of the HIV‐1 integrase (IN) catalytic …

Tubulin is a promising target for designing anti-cancer drugs. Identification of hotspots in
multifunctional Tubulin protein provides insights for new drug discovery. Although machine …

Background The pathophysiological overlap** between Sjorgen's Syndrome (SS) and
HCV, presence of anti-muscarinic receptor type 3 (M3R) antibodies in SS, the role that M3R …